NMTC · NEUROONE MEDICAL TECHNOLOGIES Corp
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 16, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Apr 16, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Aug 13, 2026TL;DR. NeuroOne reported Q3 FY2026 product revenue of $2.0M (up 16% YoY) with record 59.9% gross margins and $2.7M in new orders, received ISO 13485 certification enabling international expansion, but guided FY2026 recognized revenue to $9.2M–$10.5M versus $11.2M in orders due to supplier/manufacturing constraints, while net loss widened to $2.0M and cash fell to $2.0M.
- + Product gross margins expanded to a record 59.9% from 53.9% on favorable mix
- + New product orders grew 43% YoY to $2.7M, outpacing recognized revenue and building backlog
- + Received ISO 13485 certification ahead of schedule, enabling international commercialization with Zimmer Biomet
- − FY2026 recognized revenue guided to $9.2M–$10.5M versus $11.2M in orders due to supplier/manufacturing constraints
- − Net loss widened to $2.0M ($0.23/share basic) from $1.5M ($0.19/share) YoY
- − Cash and equivalents declined to $2.0M at June 30, 2026 from $6.6M at September 30, 2025
- − Company raising capital through dilutive ATM offerings ($0.4M in Q3 plus $1.0M post-quarter)
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NMTC
this stock
NEUROONE MEDICAL TECHNOLOGIES Corp
|
$14.75M | — | +163.5% | — | 0.9% |
|
ABT
Abbott Laboratories
|
$188.69B | -13.5% | +5.7% | 30.3 | 1.2% |
|
MDT
Medtronic plc
|
$120.46B | -2.0% | +8.4% | 23.2 | 1.1% |
|
SYK
Stryker Corp
|
$116.27B | -13.8% | +11.2% | 31.4 | 1.8% |
|
BSX
Boston Scientific Corp
|
$69.27B | -49.9% | +12.5% | 19.4 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 16, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NMTC | -8.5% | -0.6% | — | -4.7% | — |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -8.6% | -0.2% | — | -5.1% | — |